Start right, finish strong: Antibody-drug conjugate (ADC) studies for success
Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…
CertaraFebruary 23, 2026
Alternative parameters in NCA using Phoenix WinNonlin
Learn how to enhance formulation evaluation using Phoenix tools to calculate advanced PK parameters beyond…
CertaraFebruary 23, 2026
How dynamic cost calculators can be used in health economics to empower market access teams
Learn how dynamic HEOR cost calculators support budget impact, cost-effectiveness, and payer engagement to strengthen…
CertaraFebruary 19, 2026
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development
With the release of the draft ICH M15 guidance, MIDD is no longer optional -…
CertaraFebruary 18, 2026
Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development
Discover how Certara's AI-powered QSP modeling software, Certara IQ is overcoming challenges in drug development…
CertaraFebruary 17, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…
CertaraFebruary 13, 2026
